- Home
- ALEC vs NTHI Comparison
ALEC vs NTHI Comparison
Compare ALEC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- NTHI
- Stock Information
- Founded
- ALEC 2013
- NTHI 2008
- Country
- ALEC United States
- NTHI United States
- Employees
- ALEC N/A
- NTHI N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- NTHI Health Care
- Exchange
- ALEC Nasdaq
- NTHI Nasdaq
- Market Cap
- ALEC 124.0M
- NTHI 110.9M
- IPO Year
- ALEC 2019
- NTHI N/A
- Fundamental
- Price
- ALEC $1.60
- NTHI $4.97
- Analyst Decision
- ALEC Buy
- NTHI
- Analyst Count
- ALEC 8
- NTHI 0
- Target Price
- ALEC $4.50
- NTHI N/A
- AVG Volume (30 Days)
- ALEC 415.3K
- NTHI 547.1K
- Earning Date
- ALEC 08-11-2025
- NTHI 01-01-0001
- Dividend Yield
- ALEC N/A
- NTHI N/A
- EPS Growth
- ALEC N/A
- NTHI N/A
- EPS
- ALEC N/A
- NTHI N/A
- Revenue
- ALEC $88,339,000.00
- NTHI $79,990.00
- Revenue This Year
- ALEC N/A
- NTHI N/A
- Revenue Next Year
- ALEC $319.82
- NTHI N/A
- P/E Ratio
- ALEC N/A
- NTHI N/A
- Revenue Growth
- ALEC N/A
- NTHI 13.52
- 52 Week Low
- ALEC $0.87
- NTHI $3.20
- 52 Week High
- ALEC $6.52
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- ALEC 49.80
- NTHI N/A
- Support Level
- ALEC $1.74
- NTHI N/A
- Resistance Level
- ALEC $2.00
- NTHI N/A
- Average True Range (ATR)
- ALEC 0.12
- NTHI 0.00
- MACD
- ALEC -0.01
- NTHI 0.00
- Stochastic Oscillator
- ALEC 14.93
- NTHI 0.00
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").